A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

被引：5
|
作者：
Zeidan, Amer M. [1 ,2 ]
Miyazaki, Yasushi [3 ]
Platzbecker, Uwe [4 ]
Malek, Kamel [5 ]
Niolat, Julie [6 ]
Kiertsman, Flavia [7 ]
Fenaux, Pierre [8 ]
机构：
[1] Yale Univ, East Haven, CT USA
[2] Yale Canc Ctr, East Haven, CT USA
[3] Nagasaki Univ Hosp, Atom Bomb Dis Inst, Nagasaki, Japan
[4] Univ Hosp Leipzig, Leipzig, Germany
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Pharma SAS, Rueil Malmaison, France
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Univ Paris Diderot, Hop St Louis, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-127041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4259
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Randomized, double-blind phase II study of the matrix metalloprotease (MMP) inhibitor, AG3340 (Prinomastat™) in patients with myelodysplastic syndrome (MDS).
    List, AF
    Kurtin, SE
    Callander, N
    Anderson, JE
    Foran, JM
    Rabinowitz, I
    Glinsmann-Gibson, BJ
    Bellamy, WT
    Bennett, JM
    Collier, M
    Mazabel, E
    BLOOD, 2002, 100 (11) : 789A - 789A
  • [22] A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
    Wang, Eunice S.
    Lyons, Roger M.
    Larson, Richard A.
    Gandhi, Sunil
    Liu, Delong
    Matei, Carmen
    Scott, Bart
    Hu, Kuolung
    Yang, Allen S.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [23] A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
    Eunice S Wang
    Roger M Lyons
    Richard A Larson
    Sunil Gandhi
    Delong Liu
    Carmen Matei
    Bart Scott
    Kuolung Hu
    Allen S Yang
    Journal of Hematology & Oncology, 5
  • [24] Effects of high doses of selenium in septic shock: a placebo-controlled, randomized, double-blind, phase II study
    Laviolle, B.
    Forceville, X.
    Mouchel, C.
    Turmel, V.
    Annane, D.
    Bellissant, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 37 - 38
  • [25] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [26] A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA plus HR-MDS (SELECT-MDS-1).
    Dezern, Amy Elizabeth
    Marconi, Giovanni
    Deeren, Dries
    Campelo, Maria Diez
    Lubbert, Michael
    Krishnamurthy, Pramila
    Nagy, Zsolt
    Basak, Grzegorz
    Morozova, Elena
    Geissler, Klaus
    Ofran, Yishai
    Kelley, Heather
    Volkert, Angela
    Baker, Kristen
    Kang-Fortner, Qing
    Madigan, Catherine
    Roth, David A.
    Kelly, Michael
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study
    Kantarjian, Hagop M.
    Mufti, Ghulam J.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Platzbecker, Uwe
    Kuendgen, Andrea
    Gaidano, Gianluca
    Wiktor-Jedrzejczak, Wieslaw
    Bennett, John M.
    Meibohm, Anne
    Yang, Allen S.
    Giagounidis, Aristoteles
    BLOOD, 2012, 120 (21)
  • [28] Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin
    Takahashi, Toshiaki
    Hoshi, Eishin
    Takagi, Masakazu
    Katsumata, Noriyuki
    Kawahara, Masaaki
    Eguchi, Kenji
    CANCER SCIENCE, 2010, 101 (11) : 2455 - 2461
  • [29] Results of a Randomized, Double-Blind Study of Romiplostim Versus Placebo in Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome and Thrombocytopenia
    Giagounidis, Aristoteles
    Mufti, Ghulam J.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Platzbecker, Uwe
    Kuendgen, Andrea
    Gaidano, Gianluca
    Wiktor-Jedrzejczak, Wieslaw
    Hu, Kuolung
    Woodard, Paul
    Yang, Allen S.
    Kantarjian, Hagop M.
    CANCER, 2014, 120 (12) : 1838 - 1846
  • [30] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345